Bhalangki Kupar Kharmawphlang

Bhalangki Kupar Kharmawphlang

Auto-generated profile, based on publicly available information

Bhalangki Kupar Kharmawphlang

ESIC Model Hospital & PGIMSR

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2026 in International Journal of Disability, Development and Education
Verified
Journal Article
Closed access
AGAnakha Accamma George
Anakha Accamma George
DRDeepthi R
Deepthi R
BKBhalangki Kharmawphlang
Bhalangki Kharmawphlang
1. Cerebral palsy (CP) describes a group of permanent disorders of movement and posture, attributed to non-progressive disturbances in the developing foetal or infant brain, that are often accompan...

27 October 2026 in Research Square
Verified
Preprint
Open access
PDF file
BKBhalangki Kupar Kharmawphlang
Bhalangki Kupar Kharmawphlang
Background Newborn hearing screening has been part of Rashtriya Bal Swasthya Karyakram since 2013 and the National Programme for Prevention and Control of Deafness now covers 587 districts, yet most Indian screening sites test only high-risk neonates. Whether universal screening justifies its additional cost over a high-risk-register approach was identified as unresolved in 2015 and has not since been answered. A 2024 Health Technology Assessment in India analysis compared screening devices but not screening strategies. Methods A decision tree compared universal two-stage screening (otoacoustic emissions followed by automated auditory brainstem response), targeted screening of neonates with Joint Committee on Infant Hearing risk indicators, and no organised screening, in a hypothetical cohort of 100,000 Indian live births from a health system perspective. Parameters were taken from published Indian and international sources and each was tagged as published, derived or assumed. Outcomes were cases of permanent congenital hearing loss (PCHL) confirmed and incremental cost per additional case detected. One-way, threshold and 10,000-iteration probabilistic sensitivity analyses were conducted. Results Modelled two-stage sensitivity (0.891) and specificity (0.998) closely reproduced published two-step performance (0.92 and 0.98), supporting internal validity. Universal screening confirmed 305.4 of 500 PCHL cases against 163.6 under targeted screening and 50.0 with no screening, at an incremental INR 43,228 per additional case detected versus targeted screening (probabilistic median 42,775; 95% interval 18,101–202,353). The result was highly sensitive to the share of cases occurring in the high-risk group: the ICER rose from INR 30,165 at 30% to INR 539,639 at 90%, and targeted screening became non-inferior beyond roughly 95%. Notably, 38.9% of all PCHL cases remained unconfirmed even under universal screening, driven by incomplete coverage and loss to follow-up rather than test performance. Conclusions Universal screening detects substantially more cases than a high-risk-register approach, but the magnitude of that advantage rests on a parameter never measured in India — the proportion of affected infants without risk factors. The finding that more than a third of cases are missed under universal screening because of coverage and attrition suggests that strengthening follow-up systems may yield more than the choice of screening strategy. This analysis uses published secondary parameters, not primary costing, and reports cost per case detected rather than per QALY; it is therefore a structured exploration of the decision problem, not a definitive cost-effectiveness verdict.

30 September 2026 in Research Square
Verified
Preprint
Open access
PDF file
BKBhalangki Kupar Kharmawphlang
Bhalangki Kupar Kharmawphlang
DRDeepthi R
Deepthi R
SMSreenath Menon
Sreenath Menon
Background. Gastric cancer imposes a substantial but geographically uneven burden in India, with age-adjusted incidence differing roughly seven-fold between registries. India has no organised gastric cancer screening programme, and no economic evaluation has assessed whether screening would represent value for money at Indian incidence levels and Indian prices. Methods. We constructed an eight-state Markov cohort model (well; precancerous lesion; localised and advanced cancer, each undiagnosed and diagnosed; cancer death; other-cause death) with annual cycles, following a cohort of 100,000 adults from age 40 over a lifetime horizon from a health-system perspective, discounting costs and outcomes at 3% per annum. Four strategies were compared: no screening, Helicobacter pylori test-and-treat (5-yearly), serum pepsinogen (3-yearly), and universal upper gastrointestinal endoscopy (5-yearly). Natural-history transition probabilities were calibrated by least-squares to two empirical targets: an observed stage distribution at diagnosis of 39.6% localised, and registry age-adjusted incidence. Two district scenarios were calibrated separately, representing the extremes of the published Indian range. Costs were anchored to Central Government Health Scheme (CGHS) tariffs and Indian episode-of-care estimates. Incremental cost-effectiveness ratios (ICERs) were compared against an empirically derived Indian threshold of 1–1.52 times GDP per capita. Results. In the high-incidence district scenario, all screening strategies improved outcomes but at high cost. Universal endoscopy averted the most deaths (228 per 100,000; number needed to screen 439 per death averted) and produced the greatest stage shift (71.1% versus 39.6% localised at diagnosis), at an ICER of ₹456,927 per QALY versus no screening. H. pylori test-and-treat was the least costly effective option (ICER ₹396,832 per QALY). On full incremental analysis, serum pepsinogen was dominated in both scenarios. In the low-incidence district scenario, ICERs rose approximately seven-fold (H. pylori ₹2,922,758; endoscopy ₹3,249,010 per QALY). No strategy fell below 1.52 times GDP per capita in either scenario. Threshold analysis indicated that incidence would need to reach approximately 20 and 23 per 100,000 per year for H. pylori test-and-treat and endoscopy respectively to become cost-effective at 1 times GDP per capita — above every incidence rate reported by Indian population-based registries. In probabilistic sensitivity analysis (10,000 iterations), no screening was the optimal strategy in 93.9% of iterations at 1 times GDP per capita and 63.8% at 1.52 times in the high-incidence scenario, and in 100.0% of iterations at every threshold in the low-incidence scenario. Conclusions. Under the assumptions modelled, no population-wide gastric cancer screening strategy is cost-effective at contemporary Indian incidence levels and thresholds, even in the highest-incidence districts. The determining variable is not test performance but background incidence. These findings argue against universal screening and in favour of restricting any future programme to genuinely high-risk subpopulations, while prioritising the primary-data gaps — India-specific test accuracy, stage-stratified survival, and reimbursement-based episode costs — that currently limit confidence in any such evaluation.